Direxion Daily S&P Biotech Bear 3X ETF
LABD
12 hedge funds and large institutions have $8.41M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
11% more call options, than puts
Call options by funds: $610K | Put options by funds: $549K
8.41% less ownership
Funds ownership: 15.69% → 7.28% (-8.4%)
33% less funds holding
Funds holding: 18 → 12 (-6)
64% less capital invested
Capital invested by funds: $23.1M → $8.41M (-$14.7M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$362K |
| 2 |
Jane Street
New York
|
+$362K |
| 3 |
HF
HRT Financial
New York
|
+$84.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$3.92M |
| 2 |
VF
Virtu Financial
New York
|
-$2.25M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.33M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.03M |
| 5 |
TSS
Two Sigma Securities
New York
|
-$526K |
LABD Hedge Fund Activity: Q3 2017 in Review
12 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q3 2017, worth a combined $8.41M — down 64% from $23.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LABD and 1 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Barclays, opening a new position worth an estimated $362K. The largest seller was Citigroup, cutting an estimated $3.92M.
- 12 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q3 2017, down from 18 in Q2 2017.
- Funds reported $8.41M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q3 2017, down 64% quarter-over-quarter.
- 1 fund opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q3 2017 and 6 closed out, a net change of -5 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q3 2017 was Barclays, an estimated $362K added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q3 2017 was Citigroup, an estimated $3.92M sold.
Based on aggregated 13F filings for Q3 2017.